Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation
Canine indolent and aggressive lymphoma: clinical spectrum with histologic correlation
复制标题
DOI：
10.1111/vco.12048
复制
发表时间：
2015-12-01
影响因子：
2.1
通讯作者：
Marconato, L.
中科院分区：
文献类型：
--
作者：
Aresu, L.;Martini, V.;Marconato, L.
63只新诊断为淋巴瘤的狗接受了完全分期，并接受了相同的化疗。组织类型以弥漫性大B细胞淋巴瘤为主(44.4%)，其次为外周T细胞淋巴瘤(20.6%)。惰性淋巴瘤占30.2%。大多数患有侵袭性B细胞淋巴瘤的狗都患有IV期疾病。患有惰性和侵袭性T细胞淋巴瘤的狗更容易出现V期疾病，并出现症状。B细胞淋巴瘤以肝脏为主，T细胞淋巴瘤以骨髓为主。临床分期与亚期、性别、总乳酸脱氢酶(LDH)水平显著相关。侵袭性B细胞淋巴瘤更有可能得到缓解。侵袭性和惰性T细胞淋巴瘤的中位生存期为55天，惰性和侵袭性B细胞淋巴瘤的中位生存期分别为200和256天。晚期惰性淋巴瘤的预后似乎与侵袭性疾病没有明显区别。熟悉各种组织类型是做出正确诊断和驾驶治疗的关键。
Sixty-three dogs with newly diagnosed lymphoma underwent complete staging and received the same chemotherapy. Diffuse large B-cell lymphoma was the leading histotype (44.4%), followed by peripheral T-cell lymphoma (20.6%). Indolent lymphomas accounted for 30.2% of cases. Most dogs with aggressive B-cell lymphoma had stage IV disease. Dogs with indolent and aggressive T-cell lymphoma had more often stage V disease and were symptomatic. Liver and bone marrow were predominantly involved in B-cell and T-cell lymphoma, respectively. The clinical stage was significantly related to substage, sex and total lactic dehydrogenase (LDH) levels. Aggressive B-cell lymphomas were more likely to achieve remission. Median survival was 55 days for aggressive and indolent T-cell lymphoma, 200 and 256 days for indolent and aggressive B-cell lymphoma, respectively. The prognosis of advanced indolent lymphoma does not appear to be appreciably different from that of aggressive disease. Familiarity with the various histotypes is critical to make the correct diagnosis and drive therapy.